PrECOG Cancer Research Group
Innovative cancer research studies developed through industry partnerships and networks.
Supporting ECOG-ACRIN Cancer Research Group's efforts to advance cancer care
10/02/2026
PrE0510 is a randomized phase 2 clinical trial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage small cell lung cancer ( ). For more information: https://bit.ly/PrE0510
09/29/2026
Can a BCMA-targeted therapy improve outcomes in newly diagnosed multiple myeloma? PrE1005 is a randomized phase 3 trial comparing belantamab mafodotin + VRd versus daratumumab + VRd. More: https://bit.ly/pre1005-trial
09/25/2026
The PrE0510 clinical trial, led by Dr. Taofeek Owonikoko of , aims to determine the optimal dose of ivonescimab in combo with carboplatin & etoposide for patients with small cell lung cancer. More: https://bit.ly/PrE0510
09/22/2026
Dr. Shaji Kumar of is leading PrE1005, a randomized phase 3 clinical trial treating patients with newly diagnosed multiple myeloma. The study will compare two regimens to see which may lead to better and longer-lasting results. More: https://bit.ly/pre1005-trial
09/18/2026
Dr. Taofeek Owonikoko of is leading PrE0510, a phase 2 clinical trial treating patients with extensive-stage small cell lung cancer ( ) who have not yet had systemic therapy. Learn more: https://bit.ly/PrE0510
09/15/2026
PrE1005, led by Dr. Shaji Kumar of , is exploring a new treatment option for people with recently diagnosed multiple myeloma. This phase 3 clinical trial compares belantamab mafodotin + VRd versus daratumumab + VRd to determine which approach is more effective. More: https://bit.ly/pre1005-trial
09/11/2026
PrE0510 is a randomized phase 2 clinical trial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage small cell lung cancer ( ). For more information: bit.ly/PrE0510
09/04/2026
The PrE0510 clinical trial, led by Dr. Taofeek Owonikoko of , aims to determine the optimal dose of ivonescimab in combo with carboplatin & etoposide for patients with small cell lung cancer. More: bit.ly/PrE0510
08/24/2026
The PrE1702 research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive in patients not participating in a clinical trial. Learn more: https://bit.ly/pre1702-study
New video: Dr. Nisha Mohindra of Lurie Cancer Center discusses the PrE0510 , which is evaluating a new treatment for patients with extensive-stage .
Click here to claim your Sponsored Listing.
Category
Telephone
Website
Address
1818 Market Street, Suite 3000
Philadelphia, PA
19118
Opening Hours
| Monday | 9am - 5pm |
| Tuesday | 9am - 5pm |
| Wednesday | 9am - 5pm |
| Thursday | 9am - 5pm |
| Friday | 9am - 5pm |
Alerts
Be the first to know and let us send you an email when PrECOG Cancer Research Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.